Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606957 · ClinicalTrials.gov registry record · NA
The Effect of Vitamin D Repletion on Insulin Resistance
A NA study, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00606957 is a NA study that has completed, run by Rockefeller University. The registered enrollment target is 10 participants.
The verdict
NCT00606957, a NA study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The reason for doing this study is to learn whether raising a person's vitamin D level from below normal to normal levels will improve his or her body's ability to use sugar. Vitamin D is well known to be an important vitamin for the development and maintenance of bones. Recently, scientists have learned that vitamin D may have a role in the prevention of cancer, diabetes, and autoimmune diseases. The investigators are specifically interested in studying this question in the overweight/obese population as they are at greater risk for both vitamin D deficiency and impaired ability to metabolize sugar (glucose intolerance). Primary Hypotheses: Vitamin D repletion (increasing the serum 25(OH)D level from ≤ 20 ng/ml to ≥ 30 ng/ml) will improve insulin sensitivity in individuals who are overweight/obese and insulin resistant. Secondary Hypotheses: 1.Vitamin D repletion will improve biomarkers of cardiovascular risk and inflammation (directly altering macrophage cytokine production and/or indirectly as a result of improvement in insulin sensitivity.) 2.30,000 IU (0.25 mg) weekly of cholecalciferol (vitamin D3) will raise serum 25(OH)D levels from ≤ 20 ng/ml to ≥ 30 ng/ml overweight/obese population.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3 (cholecalciferol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606957
The ClinicalTrials.gov registry entry for NCT00606957 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 (cholecalciferol) is the first listed.
NCT00606957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606957 about?
NCT00606957 is a clinical study titled "The Effect of Vitamin D Repletion on Insulin Resistance". The reason for doing this study is to learn whether raising a person's vitamin D level from below normal to normal levels will improve his or her body's ability to use sugar. Vitamin D is well known to be an important vitamin for the development and maintenance of bones. Recently, scientists have le...
What is the current status of trial NCT00606957?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2008-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00606957?
The interventions under investigation include: Vitamin D3 (cholecalciferol) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00606957?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.